MapLight Therapeutics (MPLT) Return on Assets (2025)
MapLight Therapeutics recorded quarterly Return on Assets of 0.0% in Q4 2025.
MapLight Therapeutics' Return on Assets history runs 1 years deep, the most recent figure standing at 0.0% for Q4 2025.
- In Q4 2025, Return on Assets changed N/A year-over-year to 0.0%; the TTM figure through Dec 2025 stood at 0.0% (changed N/A YoY), while the FY2025 annual figure was 0.01%, changed N/A from the prior year.
- Return on Assets came in at 0.0% for Q4 2025 at MapLight Therapeutics.
- In the past five years, Return on Assets ranged from a high of 0.0% in Q4 2025 to a low of 0.0% in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROA (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -0.01% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 0.00% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -0.01% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 0.00% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 0.00% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.00% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 0.00% |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | 0.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.00% |